Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics



    SAN DIEGO, July 29 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX:
NVN) announced today that it has received a favorable decision from the
Technical Board of Appeal of the European Patent Office (EPO) for the
company's European Patent Number 1,002,110. This patent, which allows
exclusively through 2018, covers compositions of fusion proteins comprised of
a human papillomavirus (HPV) antigen fused to a heat shock protein (Hsp), as
well as DNA encoding such fusion proteins. This decision dismisses an appeal
announced on January 30, 2006, and upholds the EPO Opposition Division's
favorable decision of October 2005.
    
    (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)
    
    "We are very pleased with the Technical Board's decision to once again
uphold this important European patent," said Gregory M. McKee, president and
chief executive officer of Nventa. "This favorable ruling reaffirms the
strength of our intellectual property portfolio and reinforces an important
composition-of-matter patent covering our lead product candidate, HspE7, and
other future therapeutics for HPV-related diseases and cancer."
    
    About Nventa Biopharmaceuticals Corporation:
    
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by HPV. The company is
publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more
information about Nventa, please visit http://www.nventacorp.com.
    
    About HspE7:
    
    The company's lead product candidate, HspE7, is a novel therapeutic
candidate intended for the treatment of precancerous and cancerous lesions
caused by the human papillomavirus (HPV), one of the most common sexually
transmitted diseases in the world.  HspE7 incorporates the proprietary
adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a
substance added to vaccines to improve immune responses against target
antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion
platform, which uses recombinant DNA technology to covalently fuse stress
proteins to target antigens, thereby stimulating cellular immune system
responses. Nventa is developing HspE7 for multiple indications.




For further information:

For further information: Donna Slade, Director, Investor Relations of
Nventa Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com;
or media, Tim Brons of Vida Communication, +1-415-675-7402,
tbrons@vidacommunication.com; or Michael Moore of The Equicom Group,
+1-416-815-0700, ext. 241, mmoore@equicomgroup.com, for Nventa
Biopharmaceuticals Corporation Web Site: http://www.nventacorp.com

Organization Profile

NVENTA BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890